Breast Surgery — MCQs

Breast Surgery Indian Medical PG Practice Questions and MCQs

Question 311: Which of the following best describes the location of Level II axillary lymph nodes?

A. Lateral to pectoralis major and minor
B. Posterior to pectoralis minor (Correct Answer)
C. Medial to pectoralis minor
D. Superomedial to pectoralis major

Explanation: The classification of axillary lymph nodes into three levels is based on their anatomical relationship with the **Pectoralis minor muscle**. This is known as **Berg’s classification**, which is crucial for staging and surgical management of breast cancer. ### **Explanation of the Correct Answer** * **Level II (Middle Group):** These nodes are located **posterior (deep)** to the pectoralis minor muscle. This group also includes the **Rotter’s nodes** (interpectoral nodes), which lie between the pectoralis major and minor muscles. ### **Analysis of Incorrect Options** * **Option A (Lateral to pectoralis minor):** This describes **Level I (Lower Group)** nodes. They are located lateral and inferior to the lower border of the pectoralis minor. This group includes the anterior (pectoral), posterior (subscapular), and lateral (humeral) groups. * **Option C (Medial to pectoralis minor):** This describes **Level III (Upper Group)** nodes. They are located medial and superior to the upper border of the pectoralis minor, extending up to the lower border of the clavicle (Halsted’s ligament). * **Option D (Superomedial to pectoralis major):** This is anatomically incorrect regarding Berg’s levels; the landmark is strictly the pectoralis **minor**, not major. ### **High-Yield Clinical Pearls for NEET-PG** * **Surgical Boundary:** The pectoralis minor acts as the "key" to the axilla. * **Rotter’s Nodes:** Specifically located in Level II; their involvement can change the surgical approach. * **Axillary Vein:** Forms the superior boundary of the axillary dissection. * **Nerves to preserve:** During axillary clearance, the **Long thoracic nerve** (supplying Serratus anterior; injury causes Winging of Scapula) and the **Thoracodorsal nerve** (supplying Latissimus dorsi) must be protected. * **Sentinel Lymph Node (SLN):** Usually found in Level I; it is the first node to receive lymphatic drainage from the primary tumor.

Question 312: Clinical stage II of carcinoma breast means?

A. Tumor is limited to the breast
B. Tumor with evidence of distant metastasis
C. Tumor is present in the breast and axillary lymph nodes are involved (Correct Answer)
D. Tumor has involved breast, pectoral muscles, and a wide area of skin

Explanation: ### Explanation The staging of breast cancer primarily follows the **AJCC TNM Classification**. Clinical Stage II is considered "Early Breast Cancer" (Stage IIA) or "Locally Advanced" (Stage IIB), characterized by the involvement of the breast tissue and/or mobile ipsilateral axillary lymph nodes. **1. Why the Correct Answer is Right:** In Stage II, the tumor has typically progressed beyond the breast tissue to involve the **axillary lymph nodes (N1)** or has reached a size of **2–5 cm (T2)**. Specifically: * **Stage IIA:** T0/T1 with N1, or T2N0. * **Stage IIB:** T2N1 or T3N0. Since Option C describes the involvement of both the breast and axillary nodes, it fits the criteria for Stage II (specifically T1N1 or T2N1). **2. Analysis of Incorrect Options:** * **Option A:** Tumor limited to the breast (T1N0) defines **Stage I**. * **Option B:** Distant metastasis (M1) defines **Stage IV**, regardless of tumor size or nodal status. * **Option C:** Involvement of pectoral muscles, chest wall, or skin ulceration/satellite nodules (T4) defines **Stage IIIB**. **3. NEET-PG High-Yield Pearls:** * **Stage 0:** Carcinoma in situ (e.g., DCIS). * **Stage III:** Locally Advanced Breast Cancer (LABC). This includes T4 lesions or N2/N3 nodal involvement (fixed axillary or internal mammary nodes). * **Sentinel Lymph Node Biopsy (SLNB):** The gold standard for axillary staging in clinically N0 (node-negative) patients. * **Manchester Staging:** An older system where Stage II also specifically refers to mobile axillary lymph node involvement.

Question 313: Which type of ductal carcinoma in situ (DCIS) typically results in a palpable abnormality?

A. Comedocarcinoma
B. Non-comedo DCIS
C. Paget's disease (Correct Answer)
D. None of the above

Explanation: **Explanation:** **Paget’s Disease of the Breast** is the correct answer because it is a unique clinical presentation of DCIS where malignant cells (Paget cells) migrate from the underlying lactiferous ducts into the epidermis of the nipple-areola complex. Unlike most forms of DCIS, which are typically subclinical and detected only via microcalcifications on screening mammography, Paget’s disease presents with **palpable skin changes** (eczematous crusting, scaling, or ulceration) and is associated with an underlying palpable mass in approximately 50% of cases. **Analysis of Incorrect Options:** * **Comedocarcinoma:** This is the most aggressive subtype of DCIS characterized by high-grade nuclei and central "comedo" necrosis. While it is more likely to form larger areas of involvement, it typically presents as **microcalcifications** on mammography rather than a palpable lump. * **Non-comedo DCIS:** This includes subtypes like cribriform, papillary, and solid. These are generally lower-grade lesions that are almost exclusively detected radiologically and rarely, if ever, produce a palpable abnormality. **High-Yield Clinical Pearls for NEET-PG:** * **Pathognomonic Feature:** Presence of **Paget cells** (large cells with clear/pale cytoplasm and prominent nucleoli) within the squamous epithelium. * **Underlying Malignancy:** Nearly 100% of Paget’s disease cases have an underlying DCIS or invasive carcinoma. * **Differential Diagnosis:** Always differentiate from nipple eczema; Paget’s involves the **nipple first** and then spreads to the areola, whereas eczema usually involves the areola first. * **Staining:** Paget cells are typically **PAS positive** (mucin-producing) and **HER2/neu positive**.

Question 314: Which one of the following is the most sensitive and specific screening test to detect breast cancer?

A. Regular X-ray
B. Self breast examination
C. Mammography (Correct Answer)
D. Regular biopsy

Explanation: **Explanation:** **Mammography** is the gold standard and the most sensitive and specific screening tool for breast cancer. Its primary strength lies in its ability to detect **non-palpable lesions** and **microcalcifications** (specifically pleomorphic or linear branching types), which are often the earliest signs of Ductal Carcinoma In Situ (DCIS) or early invasive cancer, long before a lump can be felt. **Analysis of Options:** * **Self-Breast Examination (SBE):** While useful for breast awareness, SBE has a high false-positive rate and has not been shown to reduce mortality in large-scale trials. It often detects cancers at a later stage compared to imaging. * **Regular X-ray:** A standard chest or general X-ray lacks the soft-tissue resolution required to differentiate breast parenchyma from neoplastic masses. Mammography is a specialized low-dose X-ray technique designed specifically for this purpose. * **Regular Biopsy:** Biopsy (FNAC or Core Needle Biopsy) is a **diagnostic** tool, not a screening tool. It is invasive and performed only after a suspicious lesion is identified via clinical exam or imaging. **High-Yield Clinical Pearls for NEET-PG:** * **Screening Guidelines:** Most international guidelines (like ACS) recommend annual mammography starting at age 40–45. * **BI-RADS Classification:** Mammogram results are reported using the BI-RADS scale (0-6); BI-RADS 4 and 5 require biopsy. * **Young Patients:** In women under 35, **Ultrasonography (USG)** is the preferred initial investigation because young breast tissue is too dense for mammography to be effective. * **MRI:** This is the most sensitive imaging modality overall but is reserved for high-risk screening (e.g., BRCA mutations) due to lower specificity and high cost.

Question 315: An elderly female presented with 'Peau de orange appearance' of the breast. What is it likely to be associated with?

A. Drug reaction
B. Obstruction of cutaneous lymphatics (Correct Answer)
C. Postoperative scarring
D. Tumor necrosis

Explanation: **Explanation:** **Peau d’orange** (French for "orange peel skin") is a classic clinical sign of advanced breast malignancy, specifically inflammatory breast cancer. **1. Why the Correct Answer is Right:** The appearance is caused by the **obstruction of cutaneous lymphatics** by tumor emboli. When the superficial lymphatic drainage is blocked, it leads to localized lymphedema of the skin. However, the skin remains tethered to the underlying subcutaneous tissue by the **suspensory ligaments of Cooper**. As the skin swells (edema), these tethered points create characteristic "pits" or dimples, resembling the texture of an orange peel. **2. Why the Incorrect Options are Wrong:** * **A. Drug reaction:** While drug reactions can cause skin rashes or generalized edema (angioedema), they do not typically cause the localized, pitted "orange peel" texture associated with lymphatic obstruction. * **C. Postoperative scarring:** Scarring usually results in skin retraction or puckering due to fibrosis, but it lacks the diffuse edematous, pitted appearance of peau d'orange. * **D. Tumor necrosis:** Necrosis within a tumor may lead to skin ulceration or discharge, but it does not directly cause the specific lymphatic-mediated edema seen in this condition. **3. Clinical Pearls for NEET-PG:** * **Significance:** Peau d’orange is a hallmark of **Inflammatory Breast Cancer** (T4d in TNM staging). * **Differential Diagnosis:** It can also be seen in severe cases of mastitis or breast abscess, though the clinical context (fever, pain) usually differs. * **Histology:** If a skin biopsy is performed, it often shows **lymphatic invasion** by malignant cells in the dermal lymphatics. * **Staging:** The presence of peau d'orange automatically classifies the breast cancer as **Stage T4**, regardless of the size of the underlying tumor.

Question 316: A 75-year-old hypertensive lady has a 2 x 2 cm infiltrating duct cell carcinoma in the subareolar region. There are no palpable lymph nodes and no distant metastases. However, she had been treated for pulmonary tuberculosis 20 years ago. What is the best course of management?

A. Modified radical mastectomy followed by radiotherapy
B. Modified radical mastectomy followed by 6 cycles of chemotherapy
C. Breast conservation surgery followed by radiotherapy
D. Modified radical mastectomy followed by hormone therapy (Correct Answer)

Explanation: ### **Explanation** The management of breast cancer in elderly patients (≥70 years) requires balancing oncological safety with the patient's physiological age and comorbidities. **Why Option D is Correct:** 1. **Surgical Choice:** While Breast Conservation Surgery (BCS) is often preferred, a **subareolar tumor** (central location) traditionally makes BCS technically difficult or cosmetically poor, often necessitating a mastectomy. 2. **Adjuvant Therapy:** In elderly patients, the primary goal is to minimize toxicity. Most breast cancers in postmenopausal women are **Hormone Receptor (ER/PR) positive**. Hormone therapy (e.g., Tamoxifen or Aromatase Inhibitors) is highly effective and well-tolerated. 3. **The TB Factor:** This patient has a history of pulmonary tuberculosis. Radiotherapy (RT) carries a risk of radiation pneumonitis and fibrosis, which can exacerbate underlying lung damage from old TB. Therefore, avoiding RT by choosing **Modified Radical Mastectomy (MRM)** over BCS is a safer clinical decision. **Why Other Options are Incorrect:** * **Option A:** MRM usually removes the entire breast tissue and axillary nodes; post-mastectomy radiotherapy (PMRT) is generally reserved for T3-T4 tumors or ≥4 positive nodes. It is not routinely indicated for a 2 cm (T2) node-negative tumor. * **Option B:** Chemotherapy is poorly tolerated in the elderly and is typically reserved for triple-negative, HER2-positive, or high-risk luminal cancers. In a 75-year-old with a small tumor, hormone therapy is the preferred systemic choice. * **Option C:** BCS **must** always be followed by radiotherapy to reduce local recurrence. Given her age and history of pulmonary TB, the risks of RT outweigh the benefits of breast preservation. **Clinical Pearls for NEET-PG:** * **CALGB 9343 Trial:** Suggests that in women ≥70 years with early ER+ breast cancer, RT can be omitted after BCS, but MRM remains a standard if RT is contraindicated. * **Subareolar tumors:** Often require a "Central Lumpectomy" or Mastectomy due to involvement of the nipple-areola complex. * **Elderly Breast Cancer:** Usually presents with favorable biology (ER+, low grade, slow-growing).

Question 317: A mobile, variegated large lump in the breast of a 20-year-old female is most likely due to what condition?

A. Medullary carcinoma
B. Inflammatory carcinoma
C. Cystosarcoma phylloides (Correct Answer)
D. Lobular carcinoma

Explanation: **Explanation:** The correct answer is **Cystosarcoma phylloides** (Phyllodes tumor). **Why it is correct:** Phyllodes tumors are fibroepithelial neoplasms that typically present as **large, painless, mobile, and rapidly growing** breast masses. The term "variegated" refers to the heterogeneous consistency (areas of cystic degeneration, hemorrhage, and solid fleshy parts) often felt on palpation or seen on imaging/gross section. While they can occur at any age, they frequently present in younger women (though the peak incidence is slightly older than fibroadenomas). Their hallmark is the rapid increase in size, often stretching the overlying skin and appearing "bosselated." **Why the other options are incorrect:** * **Medullary Carcinoma:** Though it can be well-circumscribed and mimic a benign lesion, it is a rare subtype of invasive ductal carcinoma and typically does not reach the massive, variegated proportions seen in Phyllodes at a young age. * **Inflammatory Carcinoma:** This is a highly aggressive clinical diagnosis characterized by the "peau d'orange" appearance, warmth, and redness due to dermal lymphatic invasion. It presents as a diffuse swelling rather than a mobile, variegated lump. * **Lobular Carcinoma:** This usually presents as an ill-defined thickening rather than a discrete, mobile lump and is more common in older, postmenopausal women. **NEET-PG High-Yield Pearls:** * **Leaf-like pattern:** On histology, Phyllodes tumors show a characteristic "leaf-like" stromal overgrowth. * **Treatment:** Wide local excision with a **1 cm margin** is the gold standard. Lymph node dissection is not routinely required as these tumors spread hematogenously (like sarcomas). * **Fibroadenoma vs. Phyllodes:** If a "fibroadenoma" suddenly starts growing rapidly in a young patient, always suspect a Phyllodes tumor. * **Grading:** They can be benign, borderline, or malignant based on stromal cellularity and mitotic index.

Question 318: Which of the following is NOT a poor prognostic marker in breast cancer?

A. PCNA Positivity
B. ER positivity (Correct Answer)
C. Her 2 neu positivity
D. p53 over expression

Explanation: ### Explanation In breast cancer management, prognostic markers help predict the natural history of the disease (recurrence and survival), while predictive markers help determine the likely response to specific therapies. **Why ER Positivity is the Correct Answer:** **Estrogen Receptor (ER) positivity** is generally considered a **favorable prognostic factor**. Tumors that are ER-positive tend to be well-differentiated (lower grade), have a lower proliferation rate, and are less aggressive compared to ER-negative tumors. Furthermore, ER positivity is a strong **predictive marker** for a good response to endocrine therapies like Tamoxifen or Aromatase Inhibitors, leading to improved overall survival. **Analysis of Incorrect Options (Poor Prognostic Markers):** * **PCNA (Proliferating Cell Nuclear Antigen) Positivity:** This is a marker of cell proliferation. High levels indicate rapid tumor growth and high mitotic activity, which correlates with a poorer prognosis. * **Her-2/neu Positivity:** Overexpression of this tyrosine kinase receptor (found in ~15-20% of cases) is associated with aggressive tumor behavior, increased risk of recurrence, and resistance to conventional endocrine therapy. * **p53 Overexpression:** Mutations in the *TP53* tumor suppressor gene lead to the accumulation of stable p53 protein. This is associated with high-grade tumors, increased genomic instability, and a worse clinical outcome. **Clinical Pearls for NEET-PG:** * **Most Important Prognostic Factor:** Number of **axillary lymph nodes** involved. * **Most Important Predictive Factor:** ER/PR status (for hormonal therapy) and Her-2/neu status (for Trastuzumab). * **Triple Negative Breast Cancer (TNBC):** Lacks ER, PR, and Her-2/neu; it carries the worst prognosis among molecular subtypes. * **Cathepsin D & Ki-67:** High levels of these markers also indicate a poor prognosis.

Question 319: Which type of breast cancer has the worst prognosis?

A. Mucinous carcinoma
B. Triple negative breast carcinoma
C. Inflammatory breast carcinoma (Correct Answer)
D. Medullary breast carcinoma

Explanation: **Explanation:** The prognosis of breast cancer is determined by its clinical presentation, histological subtype, and molecular markers. **Inflammatory Breast Carcinoma (IBC)** is clinically the most aggressive form of breast cancer. It is characterized by the rapid onset of erythema, edema (peau d'orange), and warmth. The underlying pathophysiology involves the **blockage of dermal lymphatics by tumor emboli**, which leads to rapid systemic dissemination. By definition, IBC is classified as at least **Stage T4d**, meaning it is locally advanced at the time of diagnosis, leading to the worst overall survival rates among the options provided. **Analysis of Incorrect Options:** * **Mucinous (Colloid) Carcinoma:** This is a rare subtype seen typically in elderly women. It is characterized by slow growth and has a **favorable prognosis** compared to invasive ductal carcinoma (NOS). * **Medullary Carcinoma:** Despite having high-grade cytological features and being frequently associated with BRCA1 mutations, it carries a **better prognosis** than typical invasive ductal carcinoma due to a robust host immune response (lymphocytic infiltrate). * **Triple Negative Breast Carcinoma (TNBC):** While TNBC has a poor prognosis due to the lack of targeted therapies (ER, PR, and HER2 negative) and high recurrence rates, **Inflammatory Breast Cancer is clinically more lethal** and aggressive in its immediate progression. **Clinical Pearls for NEET-PG:** * **Peau d'orange:** Caused by cutaneous lymphatic edema; the skin is tethered by sweat glands, creating a dimpled appearance. * **Diagnosis:** IBC is a **clinical diagnosis**; however, a punch biopsy of the skin showing dermal lymphatic invasion is a classic pathological finding. * **Treatment:** The standard of care is Neoadjuvant Chemotherapy followed by Modified Radical Mastectomy and Radiotherapy.

Question 320: Which of the following is not a benign condition of the breast?

A. Fibroadenoma
B. Cystosarcomaphyllodes
C. Paget's disease of the nipple (Correct Answer)
D. Galactocele

Explanation: **Explanation:** The correct answer is **Paget’s disease of the nipple** because it is a form of **intraepidermal adenocarcinoma**. It is not a benign condition; rather, it is a clinical manifestation of an underlying breast malignancy. In approximately 95% of cases, Paget’s disease is associated with either an underlying **Ductal Carcinoma In Situ (DCIS)** or an invasive carcinoma. Clinically, it presents as a chronic, eczematous-like lesion of the nipple-areola complex that does not respond to topical steroids. **Analysis of Incorrect Options:** * **Fibroadenoma (A):** The most common benign breast tumor in young women ("Breast Mouse"). It arises from the terminal duct lobular unit and is characterized by a well-defined, mobile, non-tender mass. * **Cystosarcoma Phyllodes (B):** Despite the historical name "sarcoma," the majority of Phyllodes tumors (approx. 60–75%) are **benign**. While they have malignant potential, they are categorized as fibroepithelial lesions. * **Galactocele (D):** A benign milk-containing retention cyst that typically occurs in lactating women due to the blockage of a milk duct. **NEET-PG High-Yield Pearls:** * **Paget’s Disease Hallmark:** Presence of **Paget cells** (large cells with clear/pale cytoplasm and prominent nucleoli) in the epidermis. * **Clinical Tip:** Unlike simple eczema, Paget’s disease typically involves the **nipple first** and then spreads to the areola. * **Investigation of Choice:** A full-thickness **punch biopsy** of the nipple-areola complex is required for diagnosis, followed by mammography to locate the underlying malignancy.

Practice by Chapter

Breast Anatomy and Physiology

Practice Questions

Benign Breast Diseases

Practice Questions

Breast Cancer Screening

Practice Questions

Breast Cancer: Diagnosis and Staging

Practice Questions

Surgical Management of Breast Cancer

Practice Questions

Oncoplastic Breast Surgery

Practice Questions

Sentinel Lymph Node Biopsy

Practice Questions

Axillary Surgery

Practice Questions

Breast Reconstruction Techniques

Practice Questions

Male Breast Disorders

Practice Questions

Phyllodes Tumors

Practice Questions

Management of Ductal Carcinoma In Situ

Practice Questions

Want unlimited practice?

Get full access to all questions, explanations, and performance tracking.

Start For Free